Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,960 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse.
Kurosawa S, Yamaguchi H, Yamaguchi T, Fukunaga K, Yui S, Kanamori H, Usuki K, Uoshima N, Yanada M, Takeuchi J, Mizuno I, Kanda J, Okamura H, Yano S, Tashiro H, Shindo T, Chiba S, Tomiyama J, Inokuchi K, Fukuda T. Kurosawa S, et al. Among authors: okamura h. Int J Hematol. 2020 Aug;112(2):200-209. doi: 10.1007/s12185-020-02894-x. Epub 2020 Jun 3. Int J Hematol. 2020. PMID: 32495317
Efficacy and safety of intra-arterial steroid infusions in patients with steroid-resistant gastrointestinal acute graft-versus-host disease.
Nishimoto M, Koh H, Hirose A, Nakamae M, Nakane T, Hayashi Y, Okamura H, Yoshimura T, Koh S, Nanno S, Nakashima Y, Takeshita T, Yamamoto A, Sakai Y, Nishida N, Matsuoka T, Miki Y, Hino M, Nakamae H. Nishimoto M, et al. Among authors: okamura h. Exp Hematol. 2015 Dec;43(12):995-1000. doi: 10.1016/j.exphem.2015.08.002. Epub 2015 Aug 22. Exp Hematol. 2015. PMID: 26303639 Free article. Clinical Trial.
Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha.
Kurosawa S, Yamaguchi H, Yamaguchi T, Fukunaga K, Yui S, Wakita S, Kanamori H, Usuki K, Uoshima N, Yanada M, Shono K, Ueki T, Mizuno I, Yano S, Takeuchi J, Kanda J, Okamura H, Inamoto Y, Inokuchi K, Fukuda T. Kurosawa S, et al. Among authors: okamura h. Biol Blood Marrow Transplant. 2016 Jun;22(6):1125-1132. doi: 10.1016/j.bbmt.2016.03.015. Epub 2016 Mar 31. Biol Blood Marrow Transplant. 2016. PMID: 27040395 Free article.
Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation.
Yakushijin K, Ikezoe T, Ohwada C, Kudo K, Okamura H, Goto H, Yabe H, Yasumoto A, Kuwabara H, Fujii S, Kagawa K, Ogata M, Onishi Y, Kohno A, Watamoto K, Uoshima N, Nakamura D, Ota S, Ueda Y, Oyake T, Koike K, Mizuno I, Iida H, Katayama Y, Ago H, Kato K, Okamura A, Kikuta A, Fukuda T. Yakushijin K, et al. Among authors: okamura a, okamura h. Bone Marrow Transplant. 2019 May;54(5):674-680. doi: 10.1038/s41409-018-0304-4. Epub 2018 Aug 20. Bone Marrow Transplant. 2019. PMID: 30127466 Clinical Trial.
The Proportional Relationship Between Pretransplant WT1 mRNA Levels and Risk of Mortality After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Not in Remission.
Ido K, Nakamae M, Koh H, Okamura H, Nanno S, Nishimoto M, Takeoka Y, Hirose A, Nakashima Y, Hashimoto Y, Nakane T, Hino M, Nakamae H. Ido K, et al. Among authors: okamura h. Transplantation. 2019 Oct;103(10):2201-2210. doi: 10.1097/TP.0000000000002662. Transplantation. 2019. PMID: 30801534
Pretransplant serum beta-2 microglobulin level is a potential novel prognostic marker of overall survival after allogeneic hematopoietic cell transplantation - a retrospective observational study.
Harada N, Nakane T, Nakamae M, Hashimoto Y, Okamura H, Nanno S, Nishimoto M, Hirose A, Nakashima Y, Koh H, Hino M, Nakamae H. Harada N, et al. Among authors: okamura h. Transpl Int. 2020 Apr;33(4):391-401. doi: 10.1111/tri.13564. Epub 2019 Dec 27. Transpl Int. 2020. PMID: 31834655 Free article.
Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil.
Sakatoku K, Kim SW, Okamura H, Kanaya M, Kato K, Yamasaki S, Uchida N, Kobayashi H, Fukuda T, Takayama N, Ishikawa J, Nakazawa H, Sakurai M, Ikeda T, Kondo T, Yoshioka S, Miyamoto T, Kimura T, Ichinohe T, Atsuta Y, Kondo E. Sakatoku K, et al. Among authors: okamura h. Ann Hematol. 2022 Dec;101(12):2743-2757. doi: 10.1007/s00277-022-04990-w. Epub 2022 Oct 5. Ann Hematol. 2022. PMID: 36195679
Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.
Koh H, Nakamae H, Hagihara K, Nakane T, Manabe M, Hayashi Y, Nishimoto M, Umemoto Y, Nakamae M, Hirose A, Inoue E, Inoue A, Yoshida M, Bingo M, Okamura H, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Ohsawa M, Hino M. Koh H, et al. Among authors: okamura h. J Exp Clin Cancer Res. 2011 Apr 10;30(1):36. doi: 10.1186/1756-9966-30-36. J Exp Clin Cancer Res. 2011. PMID: 21477348 Free PMC article.
1,960 results